Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy

Proteome Science

Volumn 9, Issue , 2011, Pages

  Sun, Chuanyu ^a   Song, Chao ^b   Ma, Zhicheng ^a   Xu, Ke ^a   Zhang, Yang ^c   Jin, Hong ^c   Tong, Shijun ^a   Ding, Weihong ^a   Xia, Guowei ^a   Ding, Qiang ^a  

^a FUDAN UNIVERSITY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

ITRAQ Periostin; Prostate cancer; Proteomics

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN RECEPTOR; MYC PROTEIN; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR YY1;

ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEOMICS; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 79955101776     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-9-22     Document Type: Article

References (44)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003, 361:859-864. 10.1016/S0140-6736(03)12713-4, 12642065.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
3. Garnick MB. The dilemmas of prostate cancer. Sci Am 1994, 270:72-81. 10.1038/scientificamerican0494-72, 8178117.
4. Swallow T, Kirby RS. Cancer of the prostate gland. Surgery (Oxford) 2006, 24:173-176.
5. Charrier JP, Tournel C, Michel S, Comby S, Jolivet-Reynaud C, Passagot J, Dalbon P, Chautard D, Jolivet M. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis. Electrophoresis 2001, 22:1861-1816. 10.1002/1522-2683(200105)22:9<1861::AID-ELPS1861>3.0.CO;2-6, 11425243.
6. Goo YA, Goodlett DR. Advances in proteomic prostate cancer biomarker discovery. J Proteomics 2010, 73:1839-1850. 10.1016/j.jprot.2010.04.002, 20398807.
7. Balk SP, Ko Y, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003, 21:383-391. 10.1200/JCO.2003.02.083, 12525533.
8. Nash AF, Melezinek I. The role of prostate specific antigen measurement in the detection and management of prostate cancer. Endocr Relat Cancer 2000, 7:37-51. 10.1677/erc.0.0070037, 10808195.
9. Zhu G, Yan W, He H, Bi X, Han Z, Dai Q, Ye Y, Liang Y, Wang J, Zhong W. Inhibition of proliferation, invasion, and migration of prostate cancer Cells by downregulating elongation factor-1α expression. Mol Med 2009, 15:363-370. 2730347, 19707524.
10. Fidler IJ. Timeline-The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3:453-458. 10.1038/nrc1098, 12778135.
11. Mueller MM, Fusenig NE. Friends or foes-Bipolar effects of the tumour stroma in cancer. Nature Reviews Cancer 2004, 4:839-849. 10.1038/nrc1477, 15516957.
12. Sanfrancisco IF, Olumi AF, Kao AJ, Rosen S, DeWolf WC. Clinical management of prostatic intraepithelial neoplasia as diagnosed by extended needle biopsies. B J U International 2003, 91:350-354.
13. Epstein JI, Herawi M. Prostate Needle Biopsies Containing Prostatic Intraepithe-lial Neoplasi or Atypical Foci Suspicious for Carcinoma: Implications for Patient Care. J Urology 2006, 175:820-834.
14. Khamis ZI, Iczkowski KA, Sahab ZJ, Amy Sang QX. Protein Profiling of Isolated Leukocytes, Myofibroblasts, Epithelial, Basal, and Endothelial Cells from Normal, Hyperplastic, Cancerous, and Inflammatory Human Prostate Tissues. J of Cancer 2010, 1:70-79.
15. Garbis SD, Tyritzis SI, Roumeliotis T, Zerefos P, Giannopoulou EG, Vlahou A, Kossida S, Diaz J, Vourekas S, Tamvakopoulos C, Pavlakis K, Sanoudou D, Constantinides CA. Search for Potential Markers for Prostate Cancer Diagnosis, Prognosis and Treatment in Clinical Tissue Specimens Using Amine-Specific Isobaric Tagging (iTRAQ) with Two-Dimensional Liquid Chromatography and Tandem Mass Spectrometry. J Proteome Res 2008, 7:3146-3158. 10.1021/pr800060r, 18553995.
16. Wu WW, Wang G, Baek SJ, Shen RF. Comparative Study of Three Proteomic Quantitative Methods, DIGE, cICAT, and iTRAQ, Using 2D Gel- or LC-MALDI TOF/TOF. J Proteome Res 2006, 5:651-658. 10.1021/pr050405o, 16512681.
17. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ. Multiplexed protein quantitation in saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004, 3:1154-1169. 10.1074/mcp.M400129-MCP200, 15385600.
18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
19. Glen A, Gan CS, Hamdy FC, Eaton CL, Cross SS, Catto JW, Wright PC, Rehman I. iTRAQ-Facilitated Proteomic Analysis of Human Prostate Cancer Cells Identifies Proteins Associated with Progression. J Proteome Res 2008, 7:897-907. 10.1021/pr070378x, 18232632.
20. Ummanni R, Junker H, Zimmermann U, Venz S, Teller S, Giebel J, Scharf C, Woenckhaus C, Dombrowski F, Walther R. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Letters 2008, 266:171-185. 10.1016/j.canlet.2008.02.047, 18384941.
21. Lin J, Xu J, Tian H, Gao X, Chen Q, Gu Q, Xu G, Song J, Zhao F. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer 2007, 121:2596-2605. 10.1002/ijc.23016, 17722004.
22. Ummanni R, Teller S, Junker H, Zimmermann U, Venz S, Scharf C, Giebel J, Walther R. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. FEBS Journal 2008, 275:5703-5713.
23. Wong YC, Tam NN. Dedifferentiation of stromal smooth muscle as a factor in prostate carcinogenesis. Differentiation 2002, 70:633-645. 10.1046/j.1432-0436.2002.700916.x, 12492504.
24. Rosenzweig CN, Zhang Z, Sun X, Sokoll LJ, Osborne K, Partin AW, Chan DW. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol 2009, 181:1407-1414. 10.1016/j.juro.2008.10.142, 19157448.
25. Hatcher D, Daniels G, Osman I, Lee P. Molecular mechanisms involving prostate cancer racial disparity. Am J Transl Res 2009, 1:235-248. 2776319, 19956434.
26. Kim HK, Park WS, Kang SH, Warda M, Kim N, Ko JH, Prince AE, Han J. Mitochondrial alterations in human gastric carcinoma cell line. Am J Physiol Cell Physiol 2007, 293:761-771.
27. Krieg RC, Knuechel R, Schiffmann E, Liotta LA, Petricoin EF, Herrmann PC. Mitochondrial proteome: Cancer-altered metabolism associated with cytochrome c oxidase subunit level variation. Proteomics 2004, 4:2789-2795. 10.1002/pmic.200300796, 15352252.
28. Izquierdo JM, Cuezva JM. Control of the translational efficiency of β-F1 -ATPase mRNA depends on the regulation of a protein that binds the 3' untranslated region of the mRNA. Mol Cell Biol 1997, 17:5255-5268. 232376, 9271403.
29. Liu X, Wu Y, Zehner ZE. Proteomic analysis of the tumorigenic human prostate cell line M12 after microcell-mediated transfer of chromosome 19 demonstrates reduction of vimentin. Electrophoresis 2003, 24:3445-3453. 10.1002/elps.200305574, 14595690.
30. van der Poel HG, Hanrahan C, Zhong H, Simons JW. Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res 2003, 30:380-386.
31. Glaessgen A, Jonmarker S, Lindberga A, Nilsson B, Lewensohn R, Ekman P, Valdman A, Egevad L. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cance. APMIS 2008, 116:888-895. 10.1111/j.1600-0463.2008.01051.x, 19132982.
32. Liu J, Beqaj S, Yang Y, Honore B, Schuger L. Heterogeneous nuclear ribonucleoprotein-H plays a suppressive role in visceral myogenesis. Mech Dev 2001, 104:79-87. 10.1016/S0925-4773(01)00377-X, 11404082.
33. Takeshita S, Kikuno R, Tezuka K, Amann E. Osteoblast specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Bio Chem J 1993, 294:271-278.
34. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF, Kudo A. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res 1999, 14:1239-1249. 10.1359/jbmr.1999.14.7.1239, 10404027.
35. Litvin J, Selim AH, Montgomery MO, Lehmann K, Rico MC, Devlin H, Bednarik DP, Safadi FF. Expression and function of periostin-isoforms in bone. J Cell Biochem 2004, 92:1044-1061. 10.1002/jcb.20115, 15258926.
36. Ruan K, Bao S, Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 2009, 66:2219-2230. 10.1007/s00018-009-0013-7, 19308325.
37. Kudo Y, Siriwardena BS, Hatano H, Ogawa I, Takata T. Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol 2007, 22:1167-1174.
38. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res 2002, 62:5358-5364.
39. Hirose Y, Suzuki H, Amizuka N, Shimomura J, Kawano Y, Nozawa-Inoue K, Kudo A, Maeda T. Immunohistochemical localization of periostin in developing long bones of mice. Biomed Res 2003, 24:31-37.
40. Hamilton DW. Functional role of periostin in development and wound repair: implications for connective tissuedisease. J Cell Commun Signal 2008, 2:9-17. 10.1007/s12079-008-0023-5, 2570010, 18642132.
41. Dorn GW. Periostin and myocardial repair, regeneration, and recovery. N Engl J Med 2007, 357:1552-1554. 10.1056/NEJMcibr074816, 17928607.
42. Sasaki H, Sato Y, Kondo S, Fukai I, Kiriyama M, Yamakawa Y, Fuji Y. Expression of the periostin mRNA level in neuroblastoma. J Pediatr Surg 2002, 37:1293-1297. 10.1053/jpsu.2002.34985, 12194119.
43. Tsunoda T, Furusato B, Takashima Y, Ravulapalli S, Albert D, Shiv S, McLeod DG, Sesterhenn IA, Ornstein DK, Shirasawa S. The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma. Prostate 2009, 69:1398-1403. 10.1002/pros.20988, 19479898.
44. Tischler V, Fritzsche FR, Wild PJ, Stephan C, Seifert HH, Riener MO, Hermanns T, Mortezavi A, Gerhardt J, Schraml P, Jung K, Moch H, Soltermann A, Kristiansen G. Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer 2010, 10:273-281. 10.1186/1471-2407-10-273, 2903527, 20534149.